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Abstract 
 
Oxidative stress is implicated in the pathogenesis of respiratory diseases, such as COPD and its 
comorbidities, asthma, idiopathic pulmonary fibrosis and radiation pneumonitis. Antioxidants 
drugs, such as small molecule thiols, nuclear erythroid-2 related factor 2 activators and catalytic 
enzyme mimetics have been developed to target oxidant-dependent mechanisms. The 
therapeutic effects of antioxidants have been generally disappointing. A small number of 
antioxidants are approved for clinical use, such as the small molecule thiol N-acetyl-L-cysteine 
for chronic obstructive pulmonary disease, and in the United States, the superoxide dismutase 
mimetic AEOL 10150 for severe radiation pneumonitis. The future use of antioxidants for the 
treatment of chronic respiratory diseases may require a precision medicine approach to 
identify responsive patients. 
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Chemical compounds studied in this article N-acetyl-L-cysteine (PubChem CID: 12035); 
Carbocisteine (PubChem CID: 193653); Erdosteine (PubChem CID: 65632); Dimethyl fumarate 
(PubChem CID: 637568); Bardoxolone methyl CDDO (PubChem CID: 400769); AEOL-10150 
(PubChem CID: 24978527); Ebselen (PubChem CID: 3194); BXT-51072 (PubChem CID: 130165); 
Edaravane (PubChem CID: 4021); Apocynin (PubChem CID: 2214). 
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Introduction  
 
Oxidant-antioxidant (redox) balance in the respiratory system is an important component of 
host defense against pathogens. Oxidative stress occurs when oxidants overwhelm neutralizing 
antioxidants due to excess generation of free radicals, termed reactive oxygen species (ROS) 
and reactive nitrogen species (RNS) and/or due to reduced endogenous antioxidant defences 
[Figure 1]. The generation of ROS occurs from exposure to exogenous factors, such as cigarette 
smoke, atmospheric pollutants and ionizing radiation and from endogenous sources including 
inflammatory cells, such as activated macrophages and neutrophils, epithelial cells and by the 
activation of intracellular oxidative enzymes, such as nicotinamide adenine dinucleotide 
phosphate (NADPH) oxidase (NOX2). ROS contains one or more unpaired electrons, a state that 
makes them highly reactive and unstable. Important ROS that contribute to oxidative stress are 
oxygen radicals, such as the superoxide anion (O2•-) and hydroxyl radical (HO•) and nonradical 
species, such as hydrogen peroxide (H2O2). RNS include nitric oxide (•NO), peroxynitrite (ONOO-
) and nitrogen dioxide (•NO2). Antioxidant defenses against ROS occurs by the activation of the 
endogenous enzymes superoxide dismutase (SOD), catalase (CAT) and glutathione peroxidase 
(GPx) and by non-enzymatic antioxidants that include albumin, mucin and dietary sources, such 
as vitamins E (tocopherol), vitamin C (ascorbic acid), carotenoids and flavonoids.  
 
Excess oxidative stress causes DNA damage, protein carbonylation and lipid peroxidation and 
these adverse effects are thought to contribute to lung injury in respiratory diseases. Increased 
oxidative stress is implicated in the pathogenesis of chronic obstructive pulmonary disease 
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COPD [1-4] and its associated co-morbidities including cardiovascular diseases [2], osteoporosis 
[5] and skeletal muscle wasting [2,6] and in the pathogenesis of asthma [7,8], cystic fibrosis 
[9,10], bronchiectasis [11], idiopathic pulmonary fibrosis (IPF) [12,13], pulmonary hypertension 
[14] and radiation pneumonitis [15]. Detailed reviews on the pathways involved in oxidant-
antioxidant balance in chronic respiratory diseases are published elsewhere [1,3,4,16,17]. 
Targeting oxidant-dependent mechanisms is a potentially attractive approach to the treatment 
of chronic respiratory diseases and their comorbidities. This review summaries the results of 
recent clinical trials of antioxidants in several chronic diseases, discusses their place in 
management and considers the reasons for the failure of many synthetic antioxidants to reach 
the clinic.  
 
Interventions to target oxidative stress 
 
Small molecule synthetic drugs and dietary supplements have potential antioxidant properties 
that suggest that they may be effective in the treatment of respiratory diseases (Table 1). 
However, only a few of these compounds have been evaluated in large clinical trials. 
 
Small molecule thiol antioxidants 
 
Small molecule thiol drugs decrease oxidant activity by increasing the synthesis of intracellular 
glutathione levels in depleted cells, although their antioxidant effect is considered to be weak 
when glutathione levels are normal [18].  Thiol drugs also reduce disulfide bonds in mucus 
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glycoproteins to produce mucolytic effects. In the treatment of respiratory diseases that are 
associated with chronic mucus hypersecretion, it is uncertain whether the clinical benefits of 
small molecule thiol drugs are due to their antioxidant and/or mucolytic properties.  
 
N-acetyl-L-cysteine (NAC) is the most frequently investigated small molecule thiol antioxidant 
for the treatment of chronic respiratory diseases, mainly COPD and IPF. Several large 
randomized controlled clinical trials have investigated the clinical benefits of treatment with 
NAC in patients with COPD [19,20]. In the BRONCUS (Bronchitis Randomized on NAC) study, 523 
patients with COPD received 600 mg daily NAC or placebo for 3 years. NAC had no effect on the 
primary outcomes of yearly decline in FEV1 and number of exacerbations per year [19]. More 
recently, the PANTHEON (Placebo-controlled study on efficAcy and safety of N-acetylcysTeine 
High dose in Exacerbations of chronic Obstructive pulmonary disease) study investigated the 
clinical effects of higher dose NAC (600 mg twice daily) in 1006 Chinese patients with moderate 
to severe COPD [20]. Higher dose NAC reduced the rate of exacerbations, that were mainly mild 
in severity, by 22% compared with placebo over one year. A further small trial of high dose NAC 
treatment reported reductions in exacerbation rates in Chinese patients with COPD [21] who 
were at a high risk of an exacerbation [22]. A meta-analysis of 13 studies in 4155 patients with 
COPD that were treated with low dose (<600 mg daily) or high doses of NAC concluded that the 
lower dose was effective in reducing exacerbations of chronic bronchitis, whereas the higher 
dose was required to prevent exacerbations in patients with spirometric evidence of COPD [23]. 
The beneficial effects and safety of oral and inhaled NAC treatment has been investigated in 
several recent clinical trials in IPF [24-26]. The PANTHER-IPF trial (Prednisone, Azathioprine, and 
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N-Acetylcysteine: A Study That Evaluates Response in Idiopathic Pulmonary Fibrosis) reported 
that oral NAC compared to placebo resulted in no difference in the rate of decline in forced 
ventilatory capacity (FVC), death rate or acute exacerbations in patients with IPF with mild to-
moderate impairment in lung function over a 60-week period [26]. The PANAMA trial assessed 
the safety and tolerability of oral NAC or placebo for 24 weeks in 123 patients with IPF with 
background treatment of pirfenidone and reported that although NAC was well tolerated, its 
use may have increased the rate of decline in FVC [27].  
 
Carbocisteine and erdosteine are thiol antioxidant and mucolytic drugs that have been 
investigated as long-term treatments for COPD. The PEACE study reported that 1500 mg 
carbocisteine daily decreased exacerbations rates over 1 year in Chinese patients with COPD 
[28]. A systematic review and meta-analysis of 4 studies involving 1357 patients, including 
participants in the PEACE trial, concluded that long-term treatment with carbocisteine reduced 
exacerbation rates and improved the quality of life of patients with COPD [29]. The RESTORE 
(Reducing Exacerbations and Symptoms by Treatment with ORal Erdosteine in COPD) study in 
445 patients with stable moderate-to-severe COPD (GOLD stage 2 and 3) reported that the 
addition of erdosteine 600 mg daily to usual therapy compared to placebo over a 1 year 
decreased the rate of mild exacerbations, but not the rate of moderate and severe 
exacerbations and reduced the duration of exacerbations, irrespective of severity [30]. A meta-
analysis of older studies investigating the treatment effects of erdosteine 600 mg daily 
compared with placebo in patients with COPD and/or chronic bronchitis, of whom 
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approximately half were treated during an exacerbation, reported reductions in self-reported 
acute respiratory symptoms [31].  
 
A pair-wise and network meta-analysis of 11 trials of mucolytic/antioxidant agents including NAC (n=6), 
carbocisteine (n=3) and erdosteine (n=1) on COPD exacerbations demonstrated that they prevented 
exacerbations as maintenance add-on therapy to patients with frequent exacerbations (11 studies 
analyzed, odds ratio (OR) 0.51, 95% confidence interval (CI) 0.39–0.67; p < 0.001) [32]. The most 
effective drug was NAC 1,200 mg daily, whereas NAC 600 mg daily was no more effective than placebo. 
The effectiveness of mucolytic/antioxidant agents was independent of the severity of airway obstruction 
and the use of inhaled corticosteroids.  A Cochrane systematic review found no evidence of clinical 
benefit from nebulized or oral thiol derivatives in the treatment of cystic fibrosis [33].  
 
The 2017 GOLD (Global Initiative for Chronic Obstructive Lung Disease) guideline considers that 
the evidence is sufficient to indicate that NAC and carbocisteine reduce exacerbations and 
modestly improve quality of life in selected patients (Evidence A). The guideline does not 
provide recommendations about which patients, GOLD groups A to D, these drugs should be 
used [34]. The American Thoracic Society/European Respiratory Society clinical practice 
guideline on the treatment of IPF has a conditional recommendation against the use of inhaled 
or oral NAC monotherapy [24]. The US Cystic Fibrosis (CF) Foundation Pulmonary Clinical 
Practice Guidelines Committee Guideline concludes that in individuals with CF aged 6 years and 
older the evidence is insufficient to recommend for or against the chronic use of inhaled or oral 
NAC to improve lung function and quality of life or reduce exacerbations [35]. 
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Nuclear erythroid-2 related factor 2 activators 
 
Nuclear factor (erythroid-derived 2)-like 2 (Nrf2) is an important transcript factor of antioxidant 
defense [36]. The Nrf2 activating molecule sulforaphane improves phagocytosis of bacteria in 
alveolar macrophages of patients with COPD [37]. A 4 week clinical trial of sulforaphane did not 
increase Nrf2 target gene expression, decrease markers of oxidative stress or improve lung 
function in patients with COPD  [38]. The Nrf2 activator dimethyl fumarate (BG-12), which is 
approved in the US for the treatment of multiple sclerosis [39] is undergoing investigation in an 
inhaled microparticulate powder formulation for the treatment of respiratory disorders [40], 
but currently no clinical studies are underway in COPD or IPF [41].  Several synthetic CDDO (2-
cyano-3,12-dioxooleana-1,9-dien-28-oic acid) Nrf2 activators have been developed for clinical 
use [42] and of these, bardoxolone methyl CDDO is being assessed in pulmonary hypertension 
[41]. 
 
Catalytic antioxidant enzyme mimetics  
 
Catalytic antioxidant enzyme mimetics attenuate oxidative stress by restoring the action of 
depleted intracellular antioxidant enzymes, such as superoxide dismutase (SOD) and 
glutathione peroxidase (GPx) [43]. There are 3 human isoforms of SOD, each of which can 
transform O2•− to H2O2. SOD mimetics include metalloporphyrins, such as and AEOL-10150, 
macrocyclic ligands, such as M40419, and salens, such as EUK-134 or EUK-189 [17]. The U.S. 
Food and Drug Administration (FDA) recently granted fast track designation to AEOL 10150 for 
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the treatment of severe radiation pneumonitis following exposure to acute high dose radiation. 
GPx-1 is proposed as a potential therapeutic target for the treatment of COPD [44]. GPx 
mimetics include ebselen, a selenium-based organic compound and BXT-51072, although 
currently, neither compound is registered as undergoing clinical trial evaluation in respiratory 
diseases [41]. 
 
Other synthetic small molecule antioxidants 
 
In addition to the antioxidants drugs reviewed above, other synthetic small molecules have 
been developed as potential antioxidant treatments for oxidative stress in human diseases, 
including chronic respiratory diseases (Table 1). Currently, none of these compounds are 
registered as undergoing clinical trial evaluation in respiratory diseases [41]. Lipid peroxidation 
inhibitors, such as edaravane (MC-186), which is approved for the treatment of amyotrophic 
lateral sclerosis and the lazaroid antioxidant molecule, U-83836E, have been developed for 
clinical use. Inhaled glutathione does not improve clinical outcomes and markers of oxidative 
stress in cystic fibrosis [45], asthma [46] or IPF [47]. Spin traps are free radical scavengers and a 
phenyl-based nitrone spin trap derivative, disufenton sodium (NXY-059) was investigated as a 
neuroprotective agent, but it failed in clinical trials [48]. Thioredoxin mimetic peptides (redox 
sensors) attenuate oxidative stress and these compounds are undergoing pre-clinical 
development for the treatment of radiation-induced fibrosis and IPF [49]. Nebulized apocynin 
preferentially blocks NOX-2 and reduces reactive oxygen species concentrations in exhaled 
breath condensate in patients with mild asthma [50] and in COPD [51]. Neutrophilic-induced 
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tissue damage is in part induced by myeloperoxidase (MPO)-derived oxidants. Inhibitors of 
MPO have been developed [52], such as AZD3241 and  INV-315. The MPO inhibitor AZ1 inhibits 
the progression of emphysema and small airway remodeling in a smoke-induced animal model 
of COPD [53]. Selective inhibitors of inducible nitric oxide synthase (iNOS), such as GW274150 
attenuates inflammation in experimental models of COPD [54]. 
 
Naturally occurring dietary antioxidant supplements  
 
A wide range of naturally occurring dietary products have antioxidant properties (Table 1). 
Polyphenols are water-soluble molecules found in fruits, vegetables, red wine, tea and in a 
Mediterranean diet and include compounds such as resveratrol, green tea catechins and 
curcumin. Other dietary antioxidants include vitamins C and E, carotenoids, such as β-carotene, 
minerals including zinc and selenium and various nutritional supplements. A small number of 
trials have examined the effectiveness of antioxidant supplements on the treatment or 
prevention of chronic respiratory diseases or comorbidities associated with COPD. Most studies 
have shown no beneficial effects. Dietary antioxidants or vitamin supplements are not effective 
in reducing the risk of developing comorbidities that are often associated with COPD, such as 
cardiovascular disease [55] and cancer [55] or are of limited benefit in improving skeletal 
muscle dysfunction in COPD in comparison to exercise training alone [56]. Antioxidants may be 
of benefit in treating osteoporosis associated with COPD [2,5]. A systematic review of vitamin E 
supplementation reported no clinical benefits in patients with cystic fibrosis [57]. Some trials 
report improvements in clinical outcomes with antioxidant supplements in respiratory diseases. 
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For example, a large randomized trial of vitamin E supplements led to a 10% reduction in the 
risk of chronic lung disease (asthma, emphysema, chronic bronchitis, bronchiectasis) in women 
[58]. Some small clinical trials report that dietary antioxidants or vitamin supplements improve 
asthma control or lung function in children or adults  with asthma [59,60], whereas a trial of 
broccoli sprouts, which is a rich source of sulforaphane was ineffective in improving biomarkers 
of airway inflammation or clinical outcomes in adults with atopic asthma [61]. Several clinical 
trials of dietary supplements are underway for the treatment of chronic respiratory diseases, 
including one investigating the effects resveratrol in modulating metabolism and cardiovascular 
risk profile in patients with COPD [41]. 
 
Conclusions  
 
There is convincing evidence that oxidative stress is involved in the pathogenesis of respiratory 
diseases, such as COPD and its comorbidities, asthma, bronchiectasis, cystic fibrosis, idiopathic 
pulmonary fibrosis, pulmonary hypertension and radiation pneumonitis. Targeting oxidant-
dependent mechanisms should be a promising therapeutic approach to the management of 
chronic respiratory disease. Although many synthetic drugs and naturally occurring dietary 
substances have antioxidant properties, only a relatively small proportion of these agents have 
undergone clinical trial evaluation in respiratory diseases. Overall, the therapeutic effects of 
antioxidants in different respiratory diseases has been generally disappointing. Treatment with 
small molecule thiol compounds, particularly NAC, have shown improvement in clinical 
outcomes including mild exacerbations in COPD, whereas their effectiveness in preventing 
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severe exacerbation in patients receiving maximal usual therapy is less certain. The FDA 
recently granted fast track designation to the SOD mimetic AEOL 10150 for the treatment of 
severe radiation pneumonitis following exposure to acute high dose radiation. Other synthetic 
antioxidant drugs have not been approved for clinical use in the treatment for chronic 
respiratory diseases. 
 
Several reasons may explain the failure of many synthetic antioxidants to reach the clinic. 
Clinical pharmacological factors, such as inadequate dose or inappropriate route of 
administration or formulation of the antioxidant are likely to be important in some trials.  In 
other trials, there are limitations in study design, such as small sample size. Patient-related 
characteristics, such as genetic susceptibility, age, race, history of chronic bronchitis or 
exacerbations, baseline levels of redox balance, diet, and concurrent medications may also 
modify the response to antioxidants. The underlying concept that oxidative stress can be 
defined by an imbalance between pro-oxidants and antioxidants may be an oversimplification 
of redox signalling systems and in the absence of antioxidant deficiency, antioxidants may be 
ineffective in reversing oxidative stress related tissue damage [13,62].   
 
The use of antioxidants in the treatment of chronic respiratory diseases in the future may 
require the use of precision medicine to identify patients that are likely to benefit from these 
therapeutic interventions. For example, clinical trials are required to assess the benefits of 
small molecule thiol compounds in people with chronic bronchitis associated with COPD or 
asthma, including asthmatic smokers [63]. Biomarkers may help establish antioxidant deficiency 
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or a high burden of oxidative stress prior to treatment with antioxidant drugs. Genotypes of 
responsiveness to NAC, such as the gene encoding toll-interacting protein (TOLLIP) TT genotype 
[64] may identify subgroups of patients with IPF for treatment [64]. The recognition that 
oxidative stress is associated with inflammation suggests that future trials should investigate 
the therapeutic effects of the administration of antioxidants in combination with anti-
inflammatory therapies [65] or the  combination of antioxidant drugs with different modes of 
action. Finally, the finding that a Mediterranean diet supplemented with extra-virgin olive oil or 
nuts reduced the incidence of major cardiovascular events in people at a high cardiovascular 
risk [66] should prompt future trials of this diet in the management of chronic respiratory 
diseases and their comorbidities. 
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Table 1 Potential synthetic antioxidant drugs and naturally occurring dietary antioxidant 
supplements 
 
Category of antioxidant 
 
 
Examples 
Small molecule thiol antioxidants N-acetyl-L-cysteine [NAC] 
Carbocisteine 
Erdosteine 
Fudosteine 
 
Nuclear erythroid-2 related factor 2 (Nrf2) activators 
 
Sulforaphane  
Dimethyl fumarate (BG-12) 
Bardoxolone methyl CDDO  
 
Catalytic antioxidant enzyme mimetics 
 
Superoxide dismutase (SOD) mimetics 
 
 
 
Glutathione peroxidase (GPx) mimetics 
 
 
 
 
Manganese-metaloporphyrin, such as AEOL10113 
Manganese-based macrocyclic ligands, such as M40419 
Salens, such as EUK-189 
 
Ebselen 
BXT-51072 
 
Other synthetic small molecule antioxidants  
 
Lipid peroxidation inhibitors  
 
 
Glutathione 
 
Spin traps  
 
Redox sensors 
 
Nicotinamide adenine dinucleotide phosphate (NADPH) 
oxidase (NOX) inhibitors 
 
Myeloperoxidase inhibitors 
 
 
Inducible nitric oxide synthase (iNOS) inhibitors 
 
 
 
Edaravane (MC-186) 
Lazaroid antioxidant (U-83836E) 
 
Inhaled glutathione 
 
Disufenton sodium (NXY-059) 
 
Thioredoxin mimetics 
 
Nebulized apocynin 
 
 
AZD3241 
INV-315 
 
Non-selective, such as L-NAME 
Selective inhibitors, such as GW274150 
 
Naturally occurring dietary antioxidants  
 
Polyphenols (phenolic acids and flavonoids) 
 
 
 
Vitamins 
 
 
 
Resveratrol 
Green tea catechins/quercetin 
Curcumin 
 
Vitamin C (ascorbic acid) 
Vitamin E (α-tocopherol)  
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Carotenoids 
 
 
Minerals  
 
 
Nutritional supplements 
 
 
β-carotene 
Lycopene 
 
Zinc 
Selenium 
 
Acai berry 
Apocynin  
Omega-3-fatty acid 
Acetyl-L-carnitine  
 
 
Abbreviations: CDDO, the C-28 methyl ester of 2-cyano-3,12-dioxoolean-1,9-dien-28-oic acid; L-NAME, 
L-N(G)-methyl-arginine hydrochloride; 
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Figure legend 
 
Figure 1: Oxidative stress in the pathogenesis of lung damage and comorbidities 
 
Oxidative stress occurs when oxidants overwhelm neutralizing antioxidants due to excess 
generation of free radicals, termed reactive oxygen species (ROS) and reactive nitrogen species 
(RNS) and/or due to reduced endogenous antioxidant defences. The generation of ROS occurs 
from exposure to exogenous factors, such as cigarette smoke, atmospheric pollutants and 
ionizing radiation and from endogenous sources including inflammatory cells, such as activated 
macrophages and neutrophils, epithelial cells and by the activation of intracellular oxidative 
enzymes, such as nicotinamide adenine dinucleotide phosphate (NADPH) oxidase (NOX2). 
Increasing generation of ROS and RNS causes depletion of antioxidants. Antioxidant defenses 
against ROS occurs by the activation of the endogenous enzymes superoxide dismutase (SOD), 
catalase (CAT) and glutathione peroxidase (GPx) and by non-enzymatic antioxidants that 
include albumin, mucin and dietary sources, such as vitamins E (tocopherol), vitamin C (ascorbic 
acid), carotenoids and flavonoids. Excess oxidative stress causes DNA damage, protein 
carbonylation and lipid peroxidation and these adverse effects are thought to contribute to 
lung injury in respiratory diseases and the development of systemic comorbidities. 
 
Abbreviations: NO•, nitric oxide; NADPH, nicotinamide adenine dinucleotide phosphate; 
 
